Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Famotidine’s Possible Cutaneous Rash in COVID-19 Patients: An Adverse Effect Case Series

Author(s): Mohammadreza Salehi , Hossein Khalili, Zahra Jahani*, Mehrnaz Rasoolinejad and Fereshte Ghiasvanad

Volume 17, Issue 3, 2022

Published on: 11 March, 2022

Page: [269 - 273] Pages: 5

DOI: 10.2174/1574886316666211005102711

Price: $65

Abstract

Background: Various cutaneous manifestations have been observed in patients with COVID-19 infection. However, the side effects on skin of the medications used for COVID-19, such as famotidine, have not been studied.

Objective: This case series aims to present challenges in defining cutaneous manifestations of famotidine in the context of COVID-19.

Case Presentation: We identified patients from Imam Khomeini hospital complex who were admitted to the ward due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), were taking famotidine and having cutaneous rash. Clinical data were obtained through observation and intervention.

Discussion: We found 4 SARS-CoV-2 patients with cutaneous manifestations. The mean (±SD) age of the patients was 57±2 years, 3 patients were men, and their COVID-19 symptoms appeared 10±3 days before admission. The most common symptoms were cough and shortness of breath. All the patients were admitted for hypoxemic respiratory failure. Patients received famotidine for gastrointestinal prophylaxis, and all 4 patients developed Acral macular mountainous skin lesions in the upper and lower extremities, then we discontinued famotidine and lesions were recovered completely in all patients.

Conclusion: These cases prompted us to inform clinicians about cutaneous complications of famotidine in COVID-19 patients.

Keywords: COVID-19, SARS CoV-2, famotidine, cutaneous lesions, adverse effect, rash, red spot.

« Previous Next »
Graphical Abstract

[1]
Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323(16): 1574-81.
[http://dx.doi.org/10.1001/jama.2020.5394] [PMID: 32250385]
[2]
Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clinical and Exprimental Pediatric 2020; 63(4): 119-24.
[http://dx.doi.org/10.3345/cep.2020.00493] [PMID: 32252141]
[3]
Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J 2020; 55(5): 2000547.
[http://dx.doi.org/10.1183/13993003.00547-2020] [PMID: 32217650]
[4]
Choi S-H, Kim HW, Kang J-M, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clinical and Experimental Pediatric 2020; 63(4): 125-32.
[http://dx.doi.org/10.3345/cep.2020.00535] [PMID: 32252139]
[5]
Xie Y, Bowe B, Yan Y, et al. Estimates of all-cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: Cohort study. BMJ 2019; 365: l1580.
[http://dx.doi.org/10.1136/bmj.l1580] [PMID: 31147311]
[6]
Ma C, Shaheen AA, Congly SE, Andrews CN, Moayyedi P, Forbes N. Interpreting reported risks associated with use of proton pump inhibitors: Residual confounding in a 10-year analysis of national ambulatory data. Gastroenterology 2020; 158(3): 780-782.e3.
[http://dx.doi.org/10.1053/j.gastro.2019.10.023] [PMID: 31678304]
[7]
Li X, Klompas M, Menchaca JT, Young JG. Effects of daily treatment with acid suppressants for stress ulcer prophylaxis on risk of ventilator-associated events. Infect Control Hosp Epidemiol 2020; 41(2): 187-93.
[PMID: 31818336]
[8]
Lee SW, Ha EK. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: A nationwide cohort study with propensity score matching. BMJ 2020; 0: 1-9. 10.1136
[PMID: 32732368]
[9]
Janowitz T, Gablenz E, Pattinson D, et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: A case series. Gut 2020; 69(9): 1592-7.
[http://dx.doi.org/10.1136/gutjnl-2020-321852] [PMID: 32499303]
[10]
Product Information. Pepcid (famotidine). Available from:https://www.drugs.com/pregnancy/famotidine.html
[11]
Product Information. Pepcid AC (famotidine). Available from:https://pdf.hres.ca/dpd_pm/00014858.PDF
[12]
Yousefifard M. Antiviral therapy in management of COVID-19: A systematic review on current evidence. Arch Acad Emerg Mede 2020; 8(1)
[PMID: 32309809]
[13]
Mather JF, Seip RL, McKay RG. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol 2020; 115(10): 1617-23.
[http://dx.doi.org/10.14309/ajg.0000000000000832] [PMID: 32852338]
[14]
Kim YI, Park CK, Park DJ, Wi JO, Han ER, Koh YI. A case of famotidine-induced anaphylaxis. J Investig Allergol Clin Immunol 2010; 20(2): 166-9.
[PMID: 20461973]
[15]
Thakur V, Ratho RK, Kumar P, et al. Multi-organ involvement in COVID-19: beyond pulmonary manifestations. J Clin Med 2021; 10(3): 446.
[http://dx.doi.org/10.3390/jcm10030446] [PMID: 33498861]
[16]
Singh H, Kaur H, Singh K, Sen CK. Cutaneous manifestations of COVID-19: a systematic review. Adv Wound Care (New Rochelle) 2021; 10(2): 51-80.
[http://dx.doi.org/10.1089/wound.2020.1309] [PMID: 33035150]
[17]
Available from:https://www.uspharmacist.com/article/new-study-bolsters-concept-that-famotidine-can-be-helpful-in-covid19
[18]
Available from:https://www.drugs.com/sfx/famotidine-side-effects.html

Rights & Permissions Print Cite
Article Metrics
39
1
© 2024 Bentham Science Publishers | Privacy Policy